Issue 76

Mental health and psychedelic medicine

More than 280 million people suffer from depression worldwide, with many not responding to conventional treatments, and over 5,000 lives are lost to suicide in the UK each year.

Former international Scotland rugby player Rory Lamont suffered a career-ending leg break and debilitating mental health crisis, which led him to seek healing through psychedelic medicine.

Lamont will speak on his experiences with mental illness and psychedelic-assisted therapy at PSYCH Symposium: London 2022. Ahead of the industry-leading event to accelerate access to psychedelic healthcare in Europe, PSYCH spoke with Lamont on its transformative potential.

NUMINUS WELLNESS TO ACQUIRE NOVAMIND FOR C$26.2M

The company now has over a dozen psychedelic healthcare clinics across North America and four research sites.

PSILOCYBIN INCREASES BRAIN CONNECTIVITY FOR THREE WEEKS

fMRI scans conducted at Imperial College London evaluated why the psychedelic medicine is a powerful antidepressant.

BUSINESS AND INVESTMENT

Health Canada announces review of all MDMA trials.

Investors are talking about psychedelic healthcare.

Psyence partners with Clerkenwell Health on UK clinical trials.

Patients with depression turning to ketamine-assisted therapy.

Nova Mentis to supply TIPT with psilocybin.

PharmaTher licenses ketamine analogues to University of Liège’s Gesval S.A

Filament Health issued patent for psilocybin extraction.

Cybin files patent for psychedelic drug delivery technology.

PSYCH Symposium: London 2022

Tickets for the limited capacity event are selling fast. Register your attendance today to connect with key decision makers and contribute to the future of psychedelic medicine.

Speakers include:

Rick Doblin – MAPS
Benjamin Lightburn – Filament Health
Professor Celia Morgan – Awakn Life Sciences

SCIENCE AND RESEARCH

Psilocybin users are less likely to develop opioid use disorder.

Hallucinogen persisting perception disorder.

Session Spotlight

At PSYCH Symposium, Professor Matthias Liechti and Dr Friederike Holze from University of Basel will share insights from the first commercial study of LSD in over 40 years.

PROGRAMME AGENDA

REGULATION AND LEGISLATION

Maryland bill goes to governor for free psychedelic healthcare.

Oklahoma senators approve psychedelic research bill.